The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Findings With Abemaciclib Plus Tamoxifen in Advanced Breast Cancer

Erika P. Hamilton, MD
Published Online:2:44 PM, Thu January 3, 2019


Erika P. Hamilton, MD, director of the breast and gynecologic research program at Sarah Cannon Research Institute, discusses the results from a phase II study of abemaciclib (Verzenio) plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.

The progression-free survival (PFS) range was 6.5 months to 9.1 months in this study and was not statistically significant across arms. Hamilton says the single-agent abemaciclib had equal activity in regard to PFS. Hamilton also noted the arm receiving 200 mg of abemaciclib had a response rate of 29% compared to 19% in the previous MONARCH trial.

In terms of tolerability, abemaciclib was more tolerable than seen in previous studies. For instance, grade 3 diarrhea was extremely low across all arms in this trial. Hamilton also says it was clinically meaningful to look at the number of patients who reduced their dose due to diarrhea. In this trial, that number was very low.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.